News
![Bullish or Bearish? Vetting Animal Health Care Stocks: https://www.marketbeat.com/logos/articles/med_20230616064027_bullish-or-bearish-vetting-animal-health-care-stoc.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNTh5YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--60213dddc89f9c73c1d508eef5a627d55359838e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230616064027_bullish-or-bearish-vetting-animal-health-care-stoc.jpg?locale=us)
Bullish or Bearish? Vetting Animal Health Care Stocks
Dogs and cats were among the biggest beneficiaries of the pandemic thanks to more attention from housebound pet owners. Pet adoption trends also skyrocketed.
As Fido and Fluffy were spoiled more
![Clarence Seedorf und Khabib Nurmagomedov unterzeichnen mit ihrer SK Sports Holding eine weltweite Partnerschaftsvereinbarung mit FITLIGHT: https://www.irw-press.at/prcom/images/messages/2023/70999/FITLIGHT_061523_DEPRcom.001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeVF5YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--50f486fa803efa5e0e0e61eb3c214069d7373851/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/FITLIGHT_061523_DEPRcom.001.png?locale=us)
Clarence Seedorf und Khabib Nurmagomedov unterzeichnen mit ihrer SK Sports Holding eine weltweite Partnerschaftsvereinbarung mit FITLIGHT
FITLIGHT wird offizieller Technologiepartner von SK Sports Holding
MIAMI, FL / ACCESSWIRE / 15. Juni 2023 / SK Sports Holding, die im Jahr 2022 ihren ersten Seedorf Khabib Performance
![Is the Biotech Industry (IBB) Poised For A Major Breakout?: https://www.marketbeat.com/logos/articles/med_20230612064640_is-the-biotech-industry-ibb-poised-for-a-major-bre.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNThzYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--b2019bb6eec0d8ebc1d9c14bfd208c60f1847e8f/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230612064640_is-the-biotech-industry-ibb-poised-for-a-major-bre.jpg?locale=us)
Is the Biotech Industry (IBB) Poised For A Major Breakout?
The iShares Biotechnology ETF (NASDAQ: IBB) has recently shown signs of potential consolidation leading to a breakout. Such price action and development should prompt investors to notice possible
![Tax Software Specialist Vertex In Buy Zone After Base Breakout: https://www.marketbeat.com/logos/articles/med_20230609080552_tax-software-specialist-vertex-in-buy-zone-after-b.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBekVyYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--5d6fcd78862843593e6552c04e65760307d5edc4/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230609080552_tax-software-specialist-vertex-in-buy-zone-after-b.jpg?locale=us)
Tax Software Specialist Vertex In Buy Zone After Base Breakout
Tax software may not be the most glamorous business; as of today, no company in that industry has launched a virtual reality headset. However, if you’re scouting for a company with solid
![Iovance Biotherapeutics Spikes on Melanoma BLA FDA Application: https://www.marketbeat.com/logos/articles/med_20230530101326_chart-iova.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNGNlYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--5fd6ded371298788dd07c02b2ba5ece13592b28b/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230530101326_chart-iova.jpg?locale=us)
Iovance Biotherapeutics Spikes on Melanoma BLA FDA Application
Iovance Biotherapeutics Inc. (NASDAQ: IOVA) shares spiked over 20% on its advanced-stage melanoma treatment application to the U.S. Food and Drug Administration (FDA). The company submitted, and
![Pfizer Has the Prescription for Higher Share Prices: https://www.marketbeat.com/logos/articles/med_20230524125944_pfizer-has-the-prescription-for-higher-share-price.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeXdhYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--0c784121f528beec1f7021789f460466cc29d071/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230524125944_pfizer-has-the-prescription-for-higher-share-price.jpg?locale=us)
Pfizer Has the Prescription for Higher Share Prices
Pfizer Inc. (NYSE: PFE) released the results of a peer review study that sent shares up more than 5%. The study evaluated the company’s GLP-1 receptor agonist, danuglipron. The compound aimed to
![Neurimmune: Promising Phase 1 Results for Antibody NI006 in ATTR Cardiomyopathy Published in the New England Journal of Medicine: https://www.irw-press.at/prcom/images/messages/2023/70633/Accesswire-Neurimmune_220523.001.jpeg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd1lWYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--4eed58c15c2cef3ad074a955184a356e9489f7b5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Accesswire-Neurimmune_220523.001.jpeg?locale=us)
Neurimmune: Promising Phase 1 Results for Antibody NI006 in ATTR Cardiomyopathy Published in the New England Journal of Medicine
Results also presented during late-breaking session at ESC Heart Failure congress 2023
ZURICH, SWITZERLAND / ACCESSWIRE / May 20, 2023 / Neurimmune announced today that primary results of
![Is Pfizer's Seagen Deal In Jeopardy Amid Antitrust Scrutiny?: https://www.marketbeat.com/logos/articles/med_20230518141428_is-pfizers-seagen-deal-in-jeopardy-amid-antitrust.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNk1UYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--828975049b596f383745f5396fd915be2235140a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230518141428_is-pfizers-seagen-deal-in-jeopardy-amid-antitrust.jpg?locale=us)
Is Pfizer's Seagen Deal In Jeopardy Amid Antitrust Scrutiny?
Pfizer Inc. (NYSE: PFE) continued its downward trajectory on May 17, following news that the Federal Trade Commission is seeking to block Amgen Inc.’s (NASDAQ: AMGN) planned acquisition of Horizon
![Zoetis Declares New Dividend, Hinting At Undervaluation: https://www.marketbeat.com/logos/articles/med_20230518102050_zoetis-declares-new-dividend-hinting-at-undervalua.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOEVTYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3c586cb6fc0711a2c928535d3df9a038565bda71/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230518102050_zoetis-declares-new-dividend-hinting-at-undervalua.jpg?locale=us)
Zoetis Declares New Dividend, Hinting At Undervaluation
Zoetis (NYSE: ZTS) shareholders may have a new reference point to be excited about, even after witnessing some favorable developments through the company's first quarter 2023 announcements. Even
![Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings: https://www.marketbeat.com/logos/articles/med_20230518072749_vertex-pharmaceuticals-hits-record-high-on-strong.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMGtTYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--fe1fa8a76cffa1e1d1a7a5af6f98fc7532bc5f23/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230518072749_vertex-pharmaceuticals-hits-record-high-on-strong.jpg?locale=us)
Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), maker of Cystic fibrosis drugs, rallied to a record high on May 2 after a better-than-expected first-quarter earnings report.
Net income of $3.05 a
![Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential: https://www.marketbeat.com/logos/articles/med_20230517121722_analysts-say-these-2-mid-cap-biotechs-have-2x-pote.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeG9TYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--efb5d185d67469d755d9527a295e82f9c42ac310/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230517121722_analysts-say-these-2-mid-cap-biotechs-have-2x-pote.jpg?locale=us)
Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential
On May 15th, mid-cap biotechnology company Sarepta Therapeutics was the big winner in an otherwise quiet day for the Russell 1000 Index. Sarepta jumped more than 30% after an FDA advisory panel
![Saturn Oil & Gas Inc. Reports Q1 2023 Results and Record Production: https://www.irw-press.at/prcom/images/messages/2023/70599/Saturn_170523_ENPRcom.004.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNmNRYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--dfe1718b0f96e0cef29f22e19f3c3d1ee5d51975/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Saturn_170523_ENPRcom.004.png?locale=us)
Saturn Oil & Gas Inc. Reports Q1 2023 Results and Record Production
CALGARY, ALBERTA – May 16, 2023 - Saturn Oil & Gas Inc. (TSXV: SOIL)(FSE: SMKA)(OTCQX: OILSF)(“Saturn” or the “Company”) is pleased to report its financial and operating results for the three
![Saturn Oil & Gas Inc. gibt Ergebnisse für 1. Quartal 2023 und Rekordproduktion bekannt: https://www.irw-press.at/prcom/images/messages/2023/70599/Saturn_170523_DEPRcom.004.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNlFRYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--2ae4a6273fb7531fbea1a2791dc69f249162baac/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Saturn_170523_DEPRcom.004.png?locale=us)
Saturn Oil & Gas Inc. gibt Ergebnisse für 1. Quartal 2023 und Rekordproduktion bekannt
Calgary (Alberta), 16. Mai 2023 / IRW-Press / - Saturn Oil & Gas Inc. (TSX-V: SOIL) (FWB: SMKA) (OTCQX: OILSF) („Saturn“ oder das „Unternehmen“) freut sich, seine Finanz- und
![Beam Global Shines Brightly in the EV Infrastructure Space: https://www.marketbeat.com/logos/articles/med_20230516104836_beam-global-shines-brightly-in-the-ev-infrastructu.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMEFQYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a1241f963ab54587246e9c02909d2bce5f18de1f/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230516104836_beam-global-shines-brightly-in-the-ev-infrastructu.jpg?locale=us)
Beam Global Shines Brightly in the EV Infrastructure Space
Beam Global Inc. (NASDAQ: BEEM) is emerging as a standout in the electric vehicle (EV) infrastructure space. As the EV movement continues to spread as more EVs get on the road, EV charging
![The Turnaround for Weight Watchers is Taking Shape: https://www.marketbeat.com/logos/articles/med_20230514180546_charty-ww.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNGdPYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ff351f66c02189ec9ff23c0f8c44db4d7d59a6ef/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230514180546_charty-ww.jpg?locale=us)
The Turnaround for Weight Watchers is Taking Shape
Weight management meals and services provider WW International Inc. (NYSE: WW) stock made a 52-week high of $10.02 after its Q1 2023 earnings release. Shares collapsed (26%) as Artal Group S.A
![Sarepta Soars 31% As FDA Panel Backs Muscular Dystrophy Therapy: https://www.marketbeat.com/logos/articles/med_20230516050346_sarepta-soars-31-as-fda-panel-backs-muscular-dystr.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMVFPYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a31cb6b4ac8302cca8e5e70e3f6ee5c85d029040/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230516050346_sarepta-soars-31-as-fda-panel-backs-muscular-dystr.jpg?locale=us)
Sarepta Soars 31% As FDA Panel Backs Muscular Dystrophy Therapy
Sarepta Therapeutics Inc. (NASDAQ: SRPT) jumped nearly 31% on May 15, after a Food and Drug Administration committee gave a thumbs up to the company’s experimental gene therapy to treat Duchenne
![Is Novavax Finally Turning Things Around?: https://www.marketbeat.com/logos/articles/med_20230514175918_chartt-nvax.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBKzBNYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--1adde23b9a3750d2f04deb8ca4ca0a45bf6b3fef/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230514175918_chartt-nvax.jpg?locale=us)
Is Novavax Finally Turning Things Around?
Vaccine developer Novavax Inc. (NASDAQ: NVAX) stock shot up 28% following its Q1 2023 earnings report. The company specializes in vaccines for infectious diseases, including COVID-19, influenza
![German International School of Silicon Valley wird für innovatives KI-Projekt mit hochdotiertem Preis der Deutschen Industrie- und Handelskammer (IHK) ausgezeichnet: https://www.irw-press.at/prcom/images/messages/2023/70502/GermanInternationalSchool_110523_DEPRcom.003.jpeg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNFFKYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--69267da7dcc2ba0d9abbf0e2be03b974f8f1a05d/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/GermanInternationalSchool_110523_DEPRcom.003.jpeg?locale=us)
German International School of Silicon Valley wird für innovatives KI-Projekt mit hochdotiertem Preis der Deutschen Industrie- und Handelskammer (IHK) ausgezeichnet
MOUNTAIN VIEW und SAN FRANCISCO, KALIFORNIEN / ACCESSWIRE / 11. Mai 2023 / Die German International School of Silicon Valley (GISSV) wurde im Rahmen des von der Deutschen Industrie- und
![ImmunoGen Nearly Triples on Ovarian Cancer Drug Phase 3 Results: https://www.marketbeat.com/logos/articles/med_20230507142135_chartt-imgn.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNEFEYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--5c1a764fe2e456cda77e41a5778e3a020ec701a2/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230507142135_chartt-imgn.jpg?locale=us)
ImmunoGen Nearly Triples on Ovarian Cancer Drug Phase 3 Results
Commercial-state biotechnology company ImmunoGen Inc. (NASDAQ: IMGN) shares more than doubled on phase 3 clinical trial results. Its ovarian cancer drug Elahere shows statistical improvements for
![Regeneron Beats Q1 Views, But Stock Drops On Weak Eye Med Sales: https://www.marketbeat.com/logos/articles/med_20230504211613_regeneron-beats-q1-views-but-stock-drops-on-weak-e.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM2tCYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--26208beaff1e53954dadcf470598a9dc71a7ffae/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230504211613_regeneron-beats-q1-views-but-stock-drops-on-weak-e.jpg?locale=us)
Regeneron Beats Q1 Views, But Stock Drops On Weak Eye Med Sales
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) gapped down more than 6% on May 4, despite reporting better-than-expected first-quarter earnings and revenue.
Net income tumbled by 12% to $10.09 a
![High-Yield Pfizer Falls Off The COVID Cliff, And Survives: https://www.marketbeat.com/logos/articles/med_20230502093017_chart-pfe-522023.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM1Q4YWc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--c311c303e106fc0d8d8d3da758dae9bcd621a7f1/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230502093017_chart-pfe-522023.png?locale=us)
High-Yield Pfizer Falls Off The COVID Cliff, And Survives
Pfizer (NYSE: PFE) was expected to post a significant decline in revenue and earnings because of the slowing COVID business, and it did. However, the takeaway from the report is that business is
![Virios Therapeutics Up 75% on Fibromyalgia Phase 3 Proposal: https://www.marketbeat.com/logos/articles/med_20230425102047_chart-viri.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNi84YWc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e765016dc4874369137a4917d444f93993635bd3/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230425102047_chart-viri.jpg?locale=us)
Virios Therapeutics Up 75% on Fibromyalgia Phase 3 Proposal
Virios Therapeutics Inc. (NASDAQ: VIRI) is a developmental-stage biotechnology company specializing in novel antiviral therapies for treating fibromyalgia and other abnormal immune
![Why Legend Biotech Stock Is Having Its Best Month Yet: https://www.marketbeat.com/logos/articles/med_20230424135734_why-legend-biotech-stock-is-having-its-best-month.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN2I4YWc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e0fb704b76cef35f42fad2a7857b3b605b658608/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230424135734_why-legend-biotech-stock-is-having-its-best-month.jpg?locale=us)
Why Legend Biotech Stock Is Having Its Best Month Yet
Legend Biotech Corporation (NASDAQ: LEGN) is among the many healthcare names vying for a breakthrough in cancer treatment. Last week, the New Jersey-based company had just that.
On April 19th, a
![Weight Watchers Reshapes Itself with a Game-Changer Acquisition: https://www.marketbeat.com/logos/articles/med_20230411112556_chartt-ww.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeVBzYWc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3d9fc96dd5bcfbc7ab9a86816e6a4fd4a7aa020a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230411112556_chartt-ww.jpg?locale=us)
Weight Watchers Reshapes Itself with a Game-Changer Acquisition
Weight management food and services provider WW International Inc. (NYSE: WW) stock took a 25% spike as it closed its acquisition of telehealth weight loss platform provider Sequence Inc. WW
![Basilea verpartnert Onkologie-Wirkstoffkandidat Lisavanbulin mit Glioblastoma Foundation](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Basilea verpartnert Onkologie-Wirkstoffkandidat Lisavanbulin mit Glioblastoma Foundation
Allschwil, 20. Juni 2024
Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren